Sort
10,766 grants matching “checkpoint inhibitor”
Combining Immune Therapy with Targeted Therapies to Improve Melanoma Survival
$0Christine M. Lovly · Veterans Health Administration · I01 · FY2025 · VA
SMART ASSAYS FOR LIGANDS TO STUDY AND TREAT CANCER
$0Harvard University (Medical School) · P01 · FY2001 · CA
TELOMERASE ACTIVITY, TELOMERE FUNCTION, CHROMOSOME STABI
$0Johns Hopkins University · P01 · FY2001 · CA
BLRD Merit Review Research Career Scientist (RCS) Award (IK6)
$0Jin Chen · Veterans Health Administration · IK6 · FY2025 · VA
TELOMERASE ACTIVITY, TELOMERE FUNCTION, CHROMOSOME STABI
$0Johns Hopkins University · P01 · FY2001 · CA
TELOMERASE ACTIVITY, TELOMERE FUNCTION, CHROMOSOME STABI
$0Johns Hopkins University · P01 · FY2001 · CA
BLRD Research Career Scientist Award Application
$0Sushanta K Banerjee · Kansas City Va Medical Center · IK6 · FY2025 · VA
MOLECULAR CONTROL OF CELL GROWTH
$0University Of Washington · P50 · FY2001 · DK
NEW TRANSLATION INITIATION INHIBITORS FOR CANCER THERAPY
$0University Of Arizona · U19 · FY2001 · CA
Targeting lymphoid tissue residency to boost tumor immunotherapies
$0Nu Zhang · South Texas Veterans Health Care System · I01 · FY2025 · VA
Targeting mTORC2 in lung squamous cancer
$0Jin Chen · Veterans Health Administration · I01 · FY2025 · VA
MOLECULAR CONTROL OF CELL GROWTH
$0University Of Washington · P50 · FY2001 · DK
DC-HIL in cancer
$0Ponciano D Cruz · Va North Texas Health Care System · I01 · FY2024 · VA
ISOLATION OF NOVEL MECHANISM-BASED ANTITUMOR AGENTS
$0University Of Virginia Charlottesville · U19 · FY2001 · CA
BLRD Merit Review Research Career Scientist (RCS) Award (IK6)
$0Jin Chen · Veterans Health Administration · IK6 · FY2024 · VA
The Molecular Mechanism Of Cell Cycle Regulation In Budd
$0Diabetes, Digestive, Kidney Diseases · Z01 · FY2001 · DK
DNA Repair and Cell Cycle Checkpoints as Targets for Ant
$0Basic Sciences · Z01 · FY2001 · BC
Nucleic Acid Enzymes--Pol Beta And Base Repair Enzymes
$0Environmental Health Sciences · Z01 · FY2001 · ES
The long non-coding RNA LINC01133 as a novel determinant of immune evasion in triple-negative breast cancer
$0Antoine Elias Karnoub · Va Boston Health Care System · I01 · FY2024 · VA
The role of eosinophils and oxidative stress in esophageal malignancy
$0Yash Choksi · Veterans Health Administration · IK2 · FY2024 · VA
Optimizing Cell Therapy to Counter Adaptive Resistance Mechanisms in Prostate Cancer
$0Avery D. Posey · Philadelphia Va Medical Center · I01 · FY2024 · VA
Targeting NRF2 in Head and Neck Squamous Cell Carcinoma
$0Paul Zolkind · St. Louis Va Medical Center · IK2 · FY2024 · VA
Role of Sphingolipids in KRAS induced lung adenocarcinoma
$0Mark Onaitis · Va San Diego Healthcare System · I01 · FY2024 · VA
Glycocalyx Targeting and Augmenting Cellular Immunity in Lung Cancer
$0Mark M Fuster · Va San Diego Healthcare System · I01 · FY2024 · VA
Melanoma Resistance to Apoptosis: Mechanisms and Therapeutic Potential
$0Yiqun G Shellman · Va Eastern Colorado Health Care System · I01 · FY2023 · VA